澳门永利娱场官方网·(中国区)最新官方网站

About YanengBIO

Leading the Molecular Diagnostics Market in China for 22 years.

Since 2001, Yaneng BIOscience (Shenzhen) Co., Ltd. developed the first gene chip in China, YanengBIO has taken the leading position in the Molecular diagnostics market in China through 22 years of development and continuous innovation. YanengBIO have established the leading position in the Molecular diagnostics market in China. At present, the company has about 600 employees, among which the R&D department led by Ph.D team accounts for more than 20%.

At present, our core products, HPV and Thalassemia projects, have occupied No.1 place in the Chinese market, with sales revenue CAGR of 24% and annual R&D expenditure 18%.

30000000

HPV Product testing

13000000

Thalassemia gene product testing

70000000

MNP product sales

Data as of 20 October 2021

Corporate Culture

Mission

Develop Molecular Diagnostics,and Benefit Human Health.

Vision

R&D can make every laboratory enjoy the finest service brought by high-quality IVD products.

Value

Innovation drives R&D, works with agility.

Talent Team

Professional & Brilliant teams

11 PhDs, 5 talents of Peacock Plan.
R&D technicians accounted for 1/5.
Undergraduate or above employees accounted for 50%.
Average age of the team is 32 years old.

Three major R&D technology centers

Enterprise postdoctoral workstation.
Tumor liquid biopsy technological service platform.
Gene chip engineering research center.

发展
DEVELOP

2021

Probably the BEST HPV-test 2021

No.1 in national HPV EQA results for 5 years
Sail to overseas

发展
DEVELOP

2020

Development & Expansion 2020

Shenzhen's first enterprise Postdoctoral Workstation

Establish Province HPV Gene Chip R&D Center

HPV vaccine clinical research designated product

发展
DEVELOP

2019

Social Responsibility 2019

Social Responsibility Award of "China Cervical Cancer Prevention and Control Project".

发展
DEVELOP

2010-2016

Optimized Quality 2010-2016

Join FOSUN Pharma 2010
No.1 HPV & Thalassemia market share in China
100% passed the national HPV EQA
Design Thalassemia national standard

发展
DEVELOP

2004-2007

Recognized 2004-2007

Member of the WHO Cervical Cancer Screening Program
ISO13485

发展
DEVELOP

2002-2003

First Step 2002-2003

ISO9001
Developed China's first gene chip

发展
DEVELOP

2001

Established in 2001

2021

2020

2019

2010-2016

2004-2007

2002-2003

2001

Honor

ISO

Postdoctoral Workstation

HI-TECH Enterprise

National Social Responsibility Award

EAR

Honorary Certificate

1/14

Shenzhen Enterprise Postdoctoral Workstation

2020-12-01

2/14

Shenzhen Top 500 Enterprises, 2020

2020-10-17

3/14

Guangdong HPV Gene Chip Engineering Technology Research Center

2020-06-22

4/14

Infectious Disease Diagnostic Reagent Industry Technology Innovation Alliance

2020-08-10

5/14

Guangdong Province Innovation industrialization Demonstration Base of SME

2019-06-27

6/14

Special Contribution Award

2018-01-08

7/14

2017 Biological/Life health industry innovation achievement gold award

2017-11-28

8/14

Second Prize of China In Vitro Diagnostic Excellent Innovative Product Award, 2016——Severe Hemophilia A FVIII Gene Intron 22 Inverted Gene Test Kit (LD-PCR Method)

2016-10-26

9/14

Second Prize of Shenzhen Science and Technology Progress Award——Thalassemia Gene Test Kit

2015-08-10

10/14

Third Prize of Guangdong Science and Technology Award-------Thalassemia Gene Test Kit

2015-02-09

11/14

Shenzhen Science and Technology Progress Award

2012-09-10

12/14

National Key New Product Certificate——HPV Genotyping Test Kit

2011-08-16

13/14

Shenzhen Independent Innovation Product Identificatio——HPV Genotyping Test Kit (PCR-RBD), α-Thalassemia Gene Detection Kit

2011-01-25

14/14

2009 China Laboratory Medicine Annual Top10 Advanced Reagent Award——HPV Genotyping Detection Kit

2010-01-31

Social Responsibility

2021

In 2021, YanengBIO participated in the 16th Women's Day large-scale public welfare activities sponsored by the Cancer Foundation of the Communist Party of China and won the Social Responsibility Award.

Social Responsibility

2020

In 2020, with the outbreak of the COVID-19 epidemic, YanengBIO donated medical supplies worth one million yuan free of charge; during the epidemic period, YanengBIO assisted Shenzhen with the large-scale nucleic acid testing, and at the same time carried out comprehensive cooperation around the development of COVID-19 detection technology and the declaration of scientific research projects, making great contributions to the prevention and control of the epidemic in Shenzhen.

Social Responsibility

2020

In 2020, YanengBIO won the Social Welfare Award of 15th China Cancer Foundation, National Cervical Cancer and Breast Cancer Prevention and Treatment Consultation Large-scale Public Welfare Activity.

Social Responsibility

2020

In the national thalassemia public welfare activities, YanengBIO joined hands with experts in the field of thalassemia detection to spread relevant knowledge about thalassemia disease and contribute to the prevention and control of birth defects in China.

Social Responsibility

2019

Won the Social Responsibility Award in the “activity of Most Beautiful Guardian of the Cervix”, 2019.

Global